07:00 , Jul 13, 2015 |  BioCentury  |  Strategy

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc. , the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix...
07:00 , Apr 2, 2015 |  BC Innovations  |  Finance

Public Funding Notebook: Expanding access, limiting grants

Expanding access, limiting grants The push to expand access to funding for young and new investigators has led to new policies at two NIH agencies. In January, the National Institute of General Medical Sciences (NIGMS)...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Baxter International Inc, AesRx deal

Baxter acquired Orphan disease play AesRx, gaining Aes-103 , which AesRx was developing with funding from NIH’s National Center for Advancing Translational Sciences (NCATS). Financial terms of AesRx’s acquisition are undisclosed but include an upfront...
01:34 , Jul 10, 2014 |  BC Extra  |  Company News

Baxter acquires AesRx, gains NCATS-funded compound

Baxter International Inc. (NYSE:BAX) acquired Orphan disease play AesRx LLC (Newton, Mass.), gaining Aes-103 , which AesRx was developing with funding from NIH's National Center for Advancing Translational Sciences (NCATS). Financial terms of AesRx's acquisition...
08:00 , Jan 30, 2014 |  BC Innovations  |  Strategy

NCATS two years later

The National Center for Advancing Translational Sciences (NCATS) was founded at the NIH a little over two years ago, in the wake of increasing concern over the slow pace of converting scientific discoveries into new...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

Aes-103 5-hydroxymethyl-2-furfural: Phase I/IIa data

A double-blind, U.S. Phase I/IIa in 18 patients with stable sickle cell disease showed that single oral doses of 300, 1,000, 2,000, and 4,000 mg Aes-103 were well tolerated with no severe adverse events reported...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Aes-103 5-hydroxymethyl-2-furfural: Phase II start

This month, AesRx will begin a double-blind, placebo-controlled Phase II trial to evaluate Aes-103 for 28 days in up to about 100 SCD patients. The first cohort of the trial will evaluate 100 mg Aes-103...
07:00 , Jun 18, 2012 |  BioCentury  |  Finance

Reshaping blood

Reshaping blood Third Rock Ventures is the sole investor in the largest biotech series A financing thus far this year: a $40.7 million round for genetic blood disorder play Global Blood Therapeutics Inc. The biotech...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

Aes-103 5-hydroxymethyl-2-furfural: Phase I/IIa started

AesRx began a double-blind, placebo-controlled, U.S. Phase I/IIa trial to evaluate single ascending-doses of oral Aes-103 in 18 patients with stable sickle cell disease. Aes-103 has Orphan Drug designation in the U.S. for the indication....
07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Ex vivo microfluidic measurement of blood conductance to determine disease severity in patients with sickle cell disease A microfluidic device that simulates vaso-occlusive events...